The PARP inhibitor, rucaparib enhances the antitumor activity of 177Lu-DOTA-octreotate radionuclide therapy in preclinical models of neuroendocrine tumor

被引：2
|
作者：
Cullinane, Carleen [1 ]
Waldeck, Kelly [1 ]
Eu, Peter [1 ]
Hicks, Rodney J. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1800
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Promising Results After Radionuclide Therapy With 177Lu-DOTA-octreotate in Patients With Disseminated Neuroendocrine Hindgut Tumours
    Garske, U.
    Sandstrom, M.
    Johansson, S.
    Hellman, P.
    Sundin, A.
    Eriksson, B.
    Granberg, D.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S422
  • [2] Dynamic Tumour Dosimetry Model for Peptide Radionuclide Therapy with 177Lu-DOTA-Octreotate
    Konijnenberg, M. W.
    Bernard, B. F.
    De Jong, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S101 - S101
  • [3] Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
    Cullinane, Carleen
    Waldeck, Kelly
    Kirby, Laura
    Rogers, Buck E.
    Eu, Peter
    Tothill, Richard W.
    Hicks, Rodney J.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [4] Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
    Carleen Cullinane
    Kelly Waldeck
    Laura Kirby
    Buck E. Rogers
    Peter Eu
    Richard W. Tothill
    Rodney J. Hicks
    Scientific Reports, 10
  • [5] 177Lu-DOTA-octreotate Therapy of Advanced Pancreatic Neuroendocrine Tumors - a Single Centre Experience
    Fross-Baron, K.
    Garske-Roman, U.
    Welin, S.
    Granberg, D.
    Eriksson, B.
    Sandstrom, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S401 - S402
  • [6] Favourable outcome after 177Lu-DOTA-octreotate therapy of patients with neuroendocrine of the rectum -an update
    Garske-Roman, U. E.
    Sandstrom, M.
    Johansson, S.
    Fross-Baron, K.
    Sundin, A.
    Eriksson, B.
    Granberg, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S211 - S211
  • [7] Favourable outcome after 177Lu-DOTA-octreotate treatment of neuroendocrine hindgut tumours
    Garske, U. E.
    Sandstrom, M.
    Johansson, S.
    Hellman, P.
    Sundin, A.
    Eriksson, B.
    Granberg, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [8] Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival
    Loeser, Anastassia
    Schwarzenboeck, Sarah M.
    Heuschkel, Martin
    Willenberg, Holger S.
    Krause, Bernd J.
    Kurth, Jens
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (03) : 236 - 246
  • [9] Comparing the therapeutic efficacy of 67Cu-SARTATE and 177Lu-DOTA-octreotate in a neuroendocrine tumor model
    Cullinane, Carleen
    Jeffery, Charmaine
    Walker, Rachael
    Roselt, Peter
    Binns, David
    van Dam, Ellen
    Harris, Matthew
    Donnelly, Paul
    Hicks, Rodney
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [10] 177Lu-DOTA-OCTREOTATE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH FUNCTIONAL AND METASTATIC PHAEOCHROMOCYTOMA (PCC) OR PARAGANGLIOMA (PGL)
    Kong, G.
    Grozinsky-Glasberg, S.
    Callahan, J.
    Hofman, M. S.
    Meirovitz, A.
    Maimon, O.
    Pattison, D. A.
    Gross, D. J.
    Hicks, R. J.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 17 - 17
12345